ReviewThe World Allergy Organization journal2026
Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.
Review in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term prophylactic treatments (LTPs) are a major component of disease management for patients with hereditary angioedema (HAE). Patients with HAE experience considerable disease burden, as the frequent, unpredictable, and potentially life-threatening nature of HAE attacks negatively impacts patients' quality of life. LTPs aim to mitigate HAE symptoms by reducing HAE attack frequency and severity, leading to improved disease management and quality of life. As the treatment landscape has recently expanded with the addition of approved LTPs (namely, garadacimab and donidalorsen in 2025), the decision to switch between therapies is becoming increasingly common in clinical practice, and physicians and patients must carefully navigate these treatment transitions to minimize the risk of breakthrough HAE attacks and other safety concerns. Across clinical studies, treatment switching was reported for a variety of reasons, including suboptimal efficacy or frequent breakthrough attacks, safety and adverse events, family planning, treatment burden (including the LTP dosing frequency and route of administration), and drug costs and access. As these treatment options have unique mechanisms of action, durations of effect, and drug clearance rates, clinicians must carefully evaluate approaches for patients to safely switch between therapies while aiming to minimize the risk of breakthrough attacks due to lapses in prophylaxis. This review summarizes the current clinical data available in patients who have switched between first-line LTPs (namely, C1 inhibitor, lanadelumab, and berotralstat), recently approved LTPs garadacimab and donidalorsen, and second-line LTPs (androgens and antifibrinolytics) and it aims to inform health care providers as they navigate this complex treatment landscape. Clinical data available that directly evaluate or compare switching strategies between LTPs are limited, highlighting the need for further prospective studies to better characterize treatment outcomes and guide switching treatments for patients with HAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.